Triclabendazole in the treatment of human fascioliasis: a community-based study

H. El-Morshedy, A. Farghaly, S. Sharaf, L. Abou-Basha and R. Barakat

ABSTRACT The efficacy of triclabendazole in the treatment of chronic Fasciola infection was assessed. A total of 134 asymptomatic cases of established Fasciola infection were treated: 68 individuals received a single dose of 10 mg/kg and 66 individuals received 2 doses of 10 mg/kg on 2 consecutive days. Cure was assessed 5 weeks after treatment and 79.4% of the first group and 93.9% of the second group were cured. The drug was well tolerated; no serious side-effects were noted. One patient developed biochemical cholestasis the third day after treatment, but her enzyme profiles returned to normal after 2 months. We conclude triclabendazole is a safe and potent fasciolicidic drug.

Traitement de la diatomatose hépatique chez l’homme par le triclabendazole: étude communautaire

RESUME L’efficacité du triclabendazole dans le traitement de l’infection à Fasciola chronique a fait l’objet d’une évaluation. Au total, 134 cas asymptomatiques d’infection à Fasciola établis ont été traités: 68 sujets ont reçu une dose unique de 10 mg/kg et 66 sujets ont reçu deux doses de 10 mg/kg deux jours de suite. La guérison a été évaluée cinq semaines après le traitement: 79,4% des sujets du premier groupe et 93,9% de ceux du second groupe ont été guéris. Le médicament a été bien toléré; aucun effet secondaire grave n’a été noté. Une patiente a développé une cholestase biochimique trois jours après le traitement mais son profil enzymatique est revenu à la normale après 2 mois. On conclut que le triclabendazole est un médicament sûr et efficace contre les douves du genre Fasciola.

1Department of Tropical Health, High Institute of Public Health; 2Department of Parasitology, Medical Research Institute, University of Alexandria, Alexandria, Egypt.
3Department of Parasitology, Liver Institute, University of Menoufiya, Menoufiya, Egypt.
Received: 06/05/99; accepted: 30/09/99
Introduction

Abis, a rural area in the vicinity of Alexandria, Egypt, has been reporting increasing rates of human fascioliasis since the late 1970s [1–3]. Factors underlying human infection are the prevalence of Fasciola infection among herbivorous animals and the presence of the intermediate host snail (Lymnaea caulliaudi) of the fluke. Farag reported an overall prevalence of Fasciola infection of 32% among herbivorous animals without control measures [4]. The temperate climate of the area and the consumption of contaminated leafy green vegetables, a cheap source of food for inhabitants of the area, favour persistence of infection.

Because of the increasing prevalence of fascioliasis among Egyptians [1–3], the need for treatment is pressing and vital. Several drugs have been proposed for the treatment of human fascioliasis. Emetine is used because of its high efficacy in the treatment of acute and chronic infection but has significant side-effects [5–7]. Praziquantel is not effective against Fasciola infection, probably due to the thick tegument of Fasciola which hinders drug presentation [5,8,9]. Albendazole, although effective against animal fascioliasis, has a high rate of failure in human infection [10]. Bithionol is used for chronic infection only, its cure rate is near 50% and treatment must be repeated for several days with higher doses given daily [11–13].

Triclabendazole (TCBZ) is a chlorinated benzimidazole derivative. Compared with other fasciolicides it is outstanding for its high efficacy against both immature stages and adult forms of the worm simultaneously [10,14,15]. The drug is very effective and specific against both acute migratory and chronic infections in cattle [16] and in sheep [10] given in single doses of 12 mg/kg and 10 mg/kg respectively. It has been used in millions of animals in the field and proven to be extremely safe. It is currently the drug of choice in the treatment of livestock in Australia and elsewhere in the world.

The first successful human trial was in 1988 [17]; thereafter limited human trials have been reported. The drug was either given in a single dose of 10–12 mg/kg or in two doses 12–48 hours apart [18,19]. Drug tolerance was excellent and none of the patients had either secondary symptoms or important alterations in the levels of aspartate and alanine aminotransferases, alkaline phosphatase or bilirubin during or after treatment [11]. The drug, however, has never been assessed in a large sample in the field.

The present study evaluated different regimens of TCBZ for the treatment of chronic human fascioliasis under field conditions. A single or double dose each of 10 mg/kg was given for the treatment of established human Fasciola infection in Egyptians in an endemic focus.

Subjects and methods

The study protocol was approved by the Environmental Committee, High Institute of Public Health, University of Alexandria. A total of 134 individuals proven to have chronic Fasciola infection after repeated stool examinations were enrolled in the study. All were from Abis, a rural area 15 km from Alexandria. The area is endemic for Schistosoma mansoni infection. Detailed epidemiological data are described in the authors’ previous cross-sectional study [3].

Study subjects included 87 females whose ages ranged from 2 years to 60 years (mean = 16.5 years) and 47 males whose ages ranged from 5 years to 52 years (mean
Table 1 Characteristics of individuals participating in triclabendazole treatment trial

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group I single-dose therapy</th>
<th>Group II two-dose therapy</th>
<th>Test of significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of participants</td>
<td>68</td>
<td>66</td>
<td></td>
</tr>
<tr>
<td>Mean age ± s (years)</td>
<td>16.10 ± 11.02</td>
<td>14.20 ± 10.00</td>
<td>$t = 0.90$</td>
</tr>
<tr>
<td>Mean age of males ± s (years)</td>
<td>12.40 ± 6.90</td>
<td>13.80 ± 11.01</td>
<td>$t = 0.54$</td>
</tr>
<tr>
<td>Mean age of females ± s (years)</td>
<td>18.74 ± 14.00</td>
<td>14.28 ± 11.00</td>
<td>$t = 1.65$</td>
</tr>
<tr>
<td>GMEC (epg)</td>
<td>60</td>
<td>69</td>
<td></td>
</tr>
<tr>
<td>Infection prevalence of</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schistosoma mansoni (%)</td>
<td>47.0</td>
<td>56.1</td>
<td>$Z = 1.14$</td>
</tr>
</tbody>
</table>

$s = $ standard deviation
GMEC = geometric mean egg count  
$epg = $ eggs per gram of faeces

= 12.9 years). Cases were randomly divided into two groups: group I included 68 individuals (40 females and 28 males) and group II included 66 individuals (47 females and 19 males). There were no statistically significant differences between the two groups in terms of age, sex, geometric mean egg count (GMEC) of *Fasciola* infection or the prevalence of *S. mansoni* infection (Table 1). All participants in each group were subjected to the following:

1. Egg count in stools by the modified Kato–Katz technique [20]: 4 slides were examined and *Fasciola* eggs were identified and counted. All egg counts were transformed to logarithm 10. The antilog of the mean log$_{10}$ of positive slides was the GMEC.

2. Liver function tests: these included serum bilirubin, serum glutamic oxalacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) and serum alkaline phosphatase (SAP) (Beckman Astra System, AST Enzyme Reagent Kit, USA).

3. Treatment: participants were informed in detail about the protocol. TCBZ (Ciba-Geigy Laboratories, Basel, Switzerland) was offered to all participants after obtaining consent to participate in this study. Group I was given a single dose therapy, 10 mg/kg. Group II was given two doses each of 10 mg/kg on 2 consecutive days. Participants were instructed to report any secondary symptoms, such as nausea, vomiting, pain in the right hypochondrium, skin rash, jaundice, fever.

4. Follow-up: laboratory tests were repeated 5 weeks after treatment. Blood samples were taken to determine the effect of the drug on liver function tests. *Fasciola* eggs in faeces were detected using the Kato–Katz technique [20]; 4 slides were examined from a single stool sample. The persistence of eggs was considered to indicate treatment failure. In
these cases a second treatment consisting of 2 doses each of 10 mg/kg was offered. In addition, 40 of group II were followed up 1 year after TCBZ treatment.

Data were analysed using Epi-Info 5.

Results

The efficacy of TCBZ treatment is given in Table 2. The overall parasitological cure rate was 86.6%. Cure was achieved in only 79.4% of cases receiving the single dose regimen but was 93.9% in those receiving the two-dose regimen ($Z = 2.54, P < 0.05$). The 18 cases with persistent Fasciola eggs after therapy intervention included 5 males whose mean age ± standard deviation was $14.2 ± 9.3$ years and 13 females whose mean age was $16.2 ± 15.4$ years. There were no statistically significant differences between the cured and uncured cases in terms of age, sex and $S. mansoni$ infection. However, the GMEC of uncured cases (80 eggs per gram of faeces (egp)) was significantly higher than that of cured cases (63 egp) ($t = 2.29, P < 0.05$). Among the uncured cases there was a 63% reduction in GMEC 5 weeks after treatment. These patients received a second course (10 mg/kg for 2 successive days) and cure was achieved in all cases. The 40 cases of group II who received the two-dose regimen and were followed for 1 year all remained negative.

The effect of TCBZ on the liver was studied (Table 3). Before therapy, the mean values of serum bilirubin, SGOT and SGPT were found to be within normal range. No significant change was observed after ther-

### Table 3 Liver function tests before and after triclabendazole treatment

<table>
<thead>
<tr>
<th>Liver function test</th>
<th>Before treatment</th>
<th>After treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total serum bilirubin (reference range 0.1–1.0 mg/dL)</td>
<td>0.3</td>
<td>0.3</td>
</tr>
<tr>
<td>SGPT (reference range 0–60 U/L)</td>
<td>14*</td>
<td>16</td>
</tr>
<tr>
<td>SGOT (reference range 0–40 U/L)</td>
<td>19*</td>
<td>20*</td>
</tr>
</tbody>
</table>

*One patient had SGPT = 99 U/L.
*Five patients had a mean value of SGOT = 50 U/L.
SGPT = serum glutamic pyruvic transaminase
SGOT = serum glutamic oxalacetic transaminase

### Table 2 Cure rate 5 weeks after triclabendazole treatment

<table>
<thead>
<tr>
<th>Drug regimen</th>
<th>Cured Baseline GMEC (egp)</th>
<th>% cure*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td></td>
</tr>
<tr>
<td>One dose ($n = 68$)</td>
<td>54</td>
<td>59</td>
</tr>
<tr>
<td>Two doses ($n = 66$)</td>
<td>62</td>
<td>67</td>
</tr>
<tr>
<td>Total ($n = 134$)</td>
<td>116</td>
<td>63</td>
</tr>
</tbody>
</table>

*There was a statistically significant difference between the cure rates for the two regimens ($Z = 2.54, P < 0.05$).
*40 cases were followed up for 1 year after triclabendazole treatment. All remained negative.
*c18 cases remained positive after the first trial, although there was a 63% reduction in GMEC. All became negative after receiving a second round of treatment (10 mg/kg for 2 consecutive days).
GMEC = geometric mean egg count
epg = eggs per gram of faeces
apy. The drug was well tolerated; mild, colicky pain was the only complaint reported. In one case, however, clinical jaundice developed 3 days after treatment. The patient was cured parasitologically and sonographic examination revealed a distended and inflamed gall bladder. The case was followed for 2 months; the enzyme profiles returned to normal at the end of the follow-up period (Table 4).

### Discussion

A total of 134 cases of established *Fasciola* infection were diagnosed parasitologically using the Kato–Katz technique [20]. Liver function tests, SGOT, SGPT and bilirubin were normal. This agrees with the findings of other investigators [21,22]. In 14 cases of *Fasciola*-positive Egyptian children, only 2 had apparently high levels of SGOT and SGPT. The mean values of these enzymes, however, were not significantly different from those of negative controls [23].

Cure was achieved in only 79.4% of cases receiving single-dose therapy, whereas 93.9% of cases treated with two doses 24 hours apart were cured. In previous studies, the drug has been tested on individual human cases with promising results [24,25]. It was either given in a single dose of 10–12 mg/kg or in two doses each of 10 mg/kg on 2 consecutive days, especially for chronic infections [18,19]. Similar to the findings of our study, Apt et al. reported parasitological cure in 19 of 24 individuals (79.2%) receiving a single dose of TCBZ [11]. After a second round of therapy, the cure rate was 100%.

The GMEC of cured cases (63 epg) was significantly lower than that of uncured cases (80 epg). A relationship between the intensity of *Fasciola* infection and the curative dose of bithionol has been reported by many investigators [13,26–28]; the same principle may apply to TCBZ. It is worth mentioning that all the cases that remained positive after the first drug trial achieved 100% parasitological cure after a second round of treatment.

Drug tolerance was excellent. Almost all the participants were without significant secondary symptoms or alteration in the levels of liver enzymes after treatment. Other investigators have reported excellent tolerance of the drug in addition to the absence of important alterations in liver biochemical markers [11,18].

One patient, however, developed jaundice with high counts for SGOT, SGPT, SAP and bilirubin 3 days after treatment. This patient was followed up medically with regular symptomatic treatment and all markers returned to normal within 2 months. The transient alteration in the liver biochemical markers observed in this patient was probably due to disintegrated dead parasites as evidenced by the inflamed, distended gall bladder revealed by
sonographic examination. Hammouda et al. reported a similar brief episode of fever, jaundice and right abdominal pain in one patient 4 days after treatment, which was also attributed to disintegrated dead parasites [18]. Although this complication is rare, patients must be made aware of it and instructed to report it immediately to their medical facilities to exclude the possibility of obstructive jaundice.

The outstanding cure rate of the double-dose regimen of TCBZ in a fairly large number of patients, the ease of oral administration and the excellent patient compliance under field conditions, in addition to excellent drug tolerance favours the use of the double-dose regimen of TCBZ for the treatment of chronic human fascioliasis.

Acknowledgements

The authors are much indebted to the field team for the excellent technical assistance and to the population and authorities of the Abis rural area for their hospitality and friendly cooperation. The study was supported by the High Institute of Public Health, University of Alexandria as a part of the interdepartmental annual field study programme.

References


